It has been reported that low EZH2 expression, which reduces H3K27 methylation, promoted drug resistance in BRCA-2-deficient breast cancer cells by the regulation of genomic stability (Rondinelli et al., 2017). This evidence concerns the gene EZH2 and breast cancer.